Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
-
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Musc
-
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
-
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
-
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
-
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab
-
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab
-
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
-
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
-
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024